Edition:
United States

People: Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

7.25USD
2:13pm EST
Change (% chg)

$-0.15 (-2.03%)
Prev Close
$7.40
Open
$7.30
Day's High
$7.40
Day's Low
$7.00
Volume
539,328
Avg. Vol
1,682,455
52-wk High
$32.31
52-wk Low
$5.70

Kent, Richard 

Dr. Richard S. Kent, M.D., is an Independent Director of Cempra, Inc. since September 2010. Beginning in 2010, Dr. Kent became a full partner at Intersouth Partners, a venture capital firm. He was a venture partner at Intersouth Partners from 2008 to 2010. From 2002 to 2008, Dr. Kent was the President and Chief Executive Officer of Serenex, Inc., a drug development company, when it was acquired by Pfizer Inc. From 2001 until he joined Serenex, Dr. Kent was President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. Before that, he held senior executive positions at GlaxoSmithKline plc., where he was Senior Vice President of Global Medical Affairs and Chief Medical Officer, at Glaxo Wellcome plc., where he was Vice President of U.S. Medical Affairs and Group Medical Director, and at Burroughs Wellcome plc., where he was International Director of Medical Research. Dr. Kent currently serves as a director of Cytomedix, Inc., a publicly traded biopharmaceutical company, and served as a director of Inspire Pharmaceuticals, Inc. from 2004 to 2011. He also serves on the boards of several private companies. Dr. Kent holds a B.A. from the University of California, Berkley and an M.D. from the University of California, San Diego.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Garheng Kong

--

Prabhavathi Fernandes

2,321,550

Mark Hahn

1,002,860

John Bluth

--

David Moore

1,385,230

David Oldach

--
As Of  30 Dec 2014